A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

  • Cancer
  • Breast Cancer
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Active, not recruiting

This study runs in
Cities
  • Alvarado
  • Barranquilla
  • Bogotá
  • Buenos Aires
  • Cali
  • Chihuahua
  • Córdoba
  • Floridablanca
  • Fortaleza
  • La Habana
  • Lima
  • Londrina
  • Monterrey
  • Montevideo
  • Porto Alegre
  • Rio de Janeiro
  • Rosario
  • Santiago
  • São Paulo
  • Toluca
Trial Identifier:

NCT04158258 MO39485

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT04158258, MO39485 Trial Identifier
      Bevacizumab, Trastuzumab, Ado-trastuzumab emtamsine, Pertuzumab, Atezolizumab, Capecitabine Treatments
      Breast Cancer Condition
      Official Title

      A STUDY TO OBSERVE PATIENTS CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED BREAST CANCER IN LATIN AMERICA

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      Inclusion Criteria
      • Histological confirmed newly diagnosed stage I to IV (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time
      Exclusion Criteria
      • Patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (SPC) /local labeling
      • Patients not receiving the Roche studied medicinal product, but a biosimilar

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Breast Cancer

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now